Last updated on November 2019

A Study to Evaluate Risankizumab in Adult and Adolescent Subjects With Moderate to Severe Atopic Dermatitis


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Dermatitis
  • Age: Between 12 - 100 Years
  • Gender: Male or Female

Inclusion Criteria:

  • adults who are 18 years old and, where locally permissible and approved, adolescent subjects who are at least 12 years old
  • a diagnosis of atopic dermatitis (AD) with onset of symptoms at least 2 years prior to Baseline and subject meets Hanifin and Rajka criteria
  • moderate to severe AD at the Baseline Visit
  • history of inadequate response to previous topical corticosteroid and/or topical calcineurin inhibitor treatments or a medical inability to receive these treatments

Exclusion Criteria:

  • prior exposure to any biologic immunomodulatory agent or Janus kinase (JAK) inhibitor
  • concurrent treatment with systemic therapy for AD (biologic or non-biologic) or topical and/or phototherapy treatments

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.